The toxicokinetic profile of Dex40-GTMAC3-A novel polysaccharide candidate for reversal of unfractionated heparin

Frontiers in Pharmacology

Volumn 7, Issue MAR, 2016, Pages

  Sokolowska, Emilia ^a   Kalaska, Bartlomiej ^a   Kaminski, Kamil ^b   Lewandowska, Alicja ^a   Blazejczyk, Agnieszka ^c   Wietrzyk, Joanna ^c   Kasacka, Irena ^a   Szczubialka, Krzysztof ^b   Pawlak, Dariusz ^a   Nowakowska, Maria ^b   Mogielnicki, Andrzej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Dextran; Heparin; Protamine sulfate; Safety; Toxicity; Toxicokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEXTRAN 40; GLYCIDYLTRIMETHYLAMMONIUM CHLORIDE; HEMOGLOBIN; HEPARIN; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL COUNT; BLOOD CLOT LYSIS; BLOOD CLOTTING; BODY WEIGHT; BRAIN; CELL DAMAGE; CELL VACUOLE; CYTOPLASM; ENZYME ACTIVITY; ERYTHROCYTE FRAGILITY; HEART; HEMOLYSIS; HISTOPATHOLOGY; KIDNEY; LEUKOCYTE COUNT; LIVER; LIVER CELL; LUNG; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NONHUMAN; RAT; SPLEEN; THROMBOCYTE COUNT; TOXICOKINETICS; WEIGHT GAIN;

EID: 84966397538     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00060     Document Type: Article

References (80)

1. Adler, S. G., Wang, H., Ward, H. J., Cohen, A. H., and Border, W. A. (1983). Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J. Clin. Invest. 71, 487-499. doi: 10.1172/JCI110793
2. Andrew, P. M. (1978). Scanning electron microscopy of the kidney glomerular epithelium after treatment with polycations in situ and in vitro. Am. J. Anat. 153, 291-304. doi: 10.1002/aja.1001530208
3. Ansell, J., Bakhru, S. H., Laulicht, S. S., Steiner, S. S., Grosso, M., Brown, K., et al. (2014). Use of PER977 to reverse the anticoagulant effect of edoxaban. N. Engl. J. Med. 371, 2141-2142. doi: 10.1056/NEJMc1411800
4. Bakchoul, T., Zöllner, H., Amiral, J., Panzer, S., Selleng, S., Kohlmann, T., et al. (2013). Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood 121, 2821-2827. doi: 10.1182/blood-2012-10-460691
5. Becker, F. F. (1961). Studies on the hemolytic properties of protamine. J. Gen. Physiol. 44, 433-442. doi: 10.1085/jgp.44.3.433
6. Berger, G. M. B., and Abraham, P. R. (1977). Selective protamine sulphate inactivation of lipoprotein lipase and hepatic lipase in human postheparin plasma: specific lipase levels in normals and in type I hyperlipoproteinaemia. Clin. Chim. Acta. 81, 219-228. doi: 10.1016/0009-8981(77)90052-3
7. Beyerle, A., Nolte, M. W., Solomon, C., Herzog, E., and Dickneite, G. (2014). Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals. Toxicol Apl. Pharmacol. 280, 70-77. doi: 10.1016/j.taap.2014.07.019
8. Bromfield, S. M., Wilde, E., and Smith, D. K. (2013). Heparin sensing and binding-taking supramolecular chemistry towards clinical applications. Chem. Soc. Rev. 42, 9184-9195. doi: 10.1039/c3cs60278h
9. Burke, P. A. (2015). The ups and downs of clinical translation of new technologies: Déjà Vu All over again. Mol. Ther. 3, 791-792. doi: 10.1038/mt.2015.51
10. Burns, D. L., Mascioli, E. A., and Bistrian, B. R. (1995). Parenteral iron dextran therapy: a review. Nutrition 11, 163-168.
11. Butterworth, J., Lin, Y. A., Prielipp, R., Bennett, J., and James, R. (2002). The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth. Analg. 94, 514-522. doi: 10.1097/00000539-200203000-00008
12. Carroll, W. L., Callanan, M. J., and Saroff, H. A. (1959). Physical and chemical properties of protamine from the sperm of Salmon (Oncorhynchus tschawytscha). J. Biol. Chem. 234, 2314-2316. doi: 10.1042/bj0780033
13. Chang, L. C., Wrobleski, S., Wakefield, T. W., Lee, L. M., and Yang, V. C. (2001). Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS. Pharm. Sci. 3, 24-31. doi: 10.1208/ps030319
14. Chang, S. W., and Voelkel, N. F. (1989). Charge-related lung microvascular injury. Am. Rev. Respir. Dis. 139, 534-545. doi: 10.1164/ajrccm/139.2.534
15. Cook, J. J., Niewiarowski, S., Yan, Z., Schaffer, L., Lu, W., Stewart, G. J., et al. (1992). Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation 85, 1102-1109. doi: 10.1161/01.CIR.85.3.1102
16. Cudd, A., Arvinte, T., Schulz, B., and Nicolau, C. (1989). Dextran protection of erythrocytes from low-pH-induced hemolysis. FEBS. Lett. 250, 293-296. doi: 10.1016/0014-5793(89)80741-0
17. Cushing, D. J., Cooper, W. D., Cohen, M. L., McVoy, J. R., Sobel, M., and Harris, R. B. (2010). Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. Eur. J. Pharmacol. 635, 165-170. doi: 10.1016/j.ejphar.2010.03.016
18. Data, J. L., and Sies, A. S. (1974). Drugs five years later: Dextran 40. Ann. Intem. Sled. 81, 500-504. doi: 10.7326/0003-4819-81-4-500
19. Delucia, A., Wakefield, T. W, Kadell, A. M., Wroblewski, S. K., VanDort, M., and Stanley, J. C. (1993). Tissue distribution, circulating half-life, and excertion of intravenously administrated protamine sulfate. ASAIO 39, 15-18. doi: 10.1097/00002480-199307000-00115
20. Dhaneshwar, S. S., Kandpal, M., Gairola, N., and Kadam, S. S. (2006). Dextran. A promising macromolecular drug carrier. Indian. J. Pharm. Sci. 68, 705-714. doi: 10.4103/0250-474X.31000
21. Eika, C. (1972). On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand. J. Haematol. 9, 248-257. doi: 10.1111/j.1600-0609.1972.tb00937.x
22. Fairman, R. P., Sessler, C. N., Bierman, M., and Glauser, F. L. (1987). Protamine sulfate causes pulmonary hypertension and edema in isolated rat lungs. J. Appl. Physiol. 62, 1363-1367.
23. Fazavana, J., Bianchini, E. P., Saller, F., Smadja, C., Picard, V., Taverna, M., et al. (2013). A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. J. Thromb. Haemost. 11, 1128-1136. doi: 10.1111/jth.12249
24. Gale, A. J., Elias, D. J., Averell, P. M., Teirstein, P. S., Buck, M., Brown, S. D., et al. (2011). Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients. Thromb. Res. 128, e9-e13. doi: 10.1016/j.thromres.2011.03.021
25. Giknis, M., and Clifford, C. (2008). Clinical Laboratory Parameters for Crl:WI (Han). Montreal, QC: Charles Rivers Laboratories Preclinical Services.
26. Ginimuge, P. R., and Jyothi, S. D. (2010). Methylene blue: revisited. J. Anaesthesiol. Clin. Pharmacol. 26, 517-520.
27. Harwood, J. L., Riley, S. E., and Robinson, D. S. (1974). The action of protamine on clearing factor lipase and plasma triglyceride metabolism. Biochem. Biophys. Acta 337, 225-238. doi: 10.1016/0005-2760(74)90204-5
28. Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., and Weitz, J. I. (2008). Parenteral anticoagulants. Chest 133, 141S-159S. doi: 10.1378/chest.08-0689
29. Holland, C. L., Singh, A. K., McMaster, P. R., and Fang, W. (1984). Adverse reactions to protamine sulfate following cardiac surgery. Clin. Cardiol. 7, 157-162. doi: 10.1002/clc.4960070305/pdf
30. Howard, J. M., Frawley, J. P., Artz, C. P., and Sako, Y. (1955). The fate of dextran and modified gelatine in casualties with renal insufficiency. Surg. Gynecol. Obstet. 100, 207-210.
31. Hunter, F. T. (1940). A photoelectric method for the quantitative determination of erythrocyte fragility. J. Clin. Invest. 19, 691-694. doi: 10.1172/JCI101172
32. Jenkins, C. S., Packham, M. A., Kinlough-Rathbone, R. L., and Mustard, J. F. (1971). Interactions of polylysine with platelets. Blood 37, 395-412.
33. Kalaska, B., Kaminski, K., Sokolowska, E., Czaplicki, D., Kujdowicz, M., Stalinska, K., et al. (2015). Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin. PLoS ONE 10:e0119486. doi: 10.1371/journal.pone.0119486
34. Kalaska, B., Sokolowska, E., Kaminski, K., Szczubialka, K., Mogielnicki, A., Nowakowska, M., et al. (2012). Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. EJP 686, 81-89. doi: 10.1016/j.ejphar.2012.04.037
35. Kaminski, K., Kalaska, B., Koczurkiewicz, P., Michalik, M., Szczubialka, K., Mogielnicki, A., et al. (2014). New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal. Med.Chem.Comm. 5, 489-495. doi: 10.1039/C3MD00374D
36. Kaminski, K., Plonka, M., Ciejka, J., Szczubialka, K., Nowakowska, M., Lorkowska, B., et al. (2011). Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists. J. Med. Chem. 54, 6586-6596. doi: 10.1021/jm200380w
37. Kaminski, K., Szczubialka, K., Zazakowny, K., Lach, R., and Nowakowska, M. (2010). Chitosan derivatives as novel potential heparin reversal agents. J. Med. Chem. 53, 4141-4147. doi: 10.1021/jm1001666
38. Kaminski, K., Zazakowny, K., Szczubialka, K., and Nowakowska, M. (2008). pH-Sensitive genipin-cross-linked chitosan microspheres for heparin removal. Biomacromolecules 9, 3127-3132. doi: 10.1021/bm800724q
39. Kaplan, A. I., and Sabin, S. (1975). Dextran 40: another cause of drug-induced noncardiogenic pulmonary edema. Chest 68, 376-377. doi: 10.1378/chest.68.3.376
40. Katz, N. M., Kim, Y. D., Siegelman, R., Ved, S. A., Ahmed, S. W., and Wallace, R. B. (1987). Hemodynamics of protamine administration: comparison of right atrial, left atrial and aortic injections. J. Thorac. Cardiovasc. Surg. 94, 881-886.
41. Kief, H. (1969). Morphological findings following single or multiple administration of gelatin plasma substitutes. Bibl. Haematol. 33, 367-379. doi: 10.1159/000384859
42. Kikura, M., Lee, M. K., and Levy, J. H. (1996). Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth. Analog. 83, 223-227. doi: 10.1097/00000539-199608000-00004
43. Kitazawa, I., Shino, I., Agawa, Y., Suehiro-Narita, M., Hashizume, N., Minamisawa, Y., et al. (2014). Effects of reported intravenous administration of Dextrans, water-soluble macromolecules, in rats. J. Toxicol. Pathol. 27, 231-234. doi: 10.1293/tox.2013-0067
44. Klotz, U., and Kroemer, H. (1987). Clinical pharmacokinetic considerations in the use of plasma expanders. Clin. Pharmacokinet. 12, 123-135. doi: 10.2165/00003088-198712020-00003
45. Koslow, A. R., DeFouw, D. O., Farad, M. D., Curl, G. R., Shumko, J. Z., Feinberg, R. N., et al. (1987). Protamine-induced pulmonary edema in rats. Curr Surg. 44, 219-224.
46. Kurihara, H., Anderson, J. M., Kerjaschki, D., and Farquhar, M. G. (1992). The altered glomerular filtration slits seen in puromycin aminonucleoside nephrosis and protamine sulfate-treated rats contain the tight junction protein ZO-1. Am. J. Pathol. 141, 805-816.
47. Lake, J. R., Licko, V., Van Dyke, R. W., and Scharschmidt, B. F. (1985). Biliary secretion of fluid-phase markers by the isolated perfused rat liver. Role of transcellular vesicular transport. J. Clin. Invest. 76, 676-684. doi: 10.1172/JCI112021
48. Larsen, L. (1989). Dextran prodrugs-structure and stability in relation to therapeutic activity. Adv. Drug. Deliv. Rev. 3, 103-154. doi: 10.1016/0169-409X(89)90006-9
49. Legendre, C., Thervet, E., Page, B., Percheron, A., Noel, L. H., and Kreis, H. (1993). Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 342, 248-249. doi: 10.1016/0140-6736(93)92345-T
50. Lowenstein, E., Johnston, W. E., Lappas, D. G., D'Ambra, M. N., Schneider, R. C., Dagget, W. M., et al. (1983). Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology 59, 470-473. doi: 10.1097/00132586-198408000-00026
51. Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., et al. (2013). A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446-451. doi: 10.1038/nm.3102
52. Lu, M. H., Hinson, W. G., He, D., Turturro, A., and Hart, R. W. (1993). Hepatic nuclear ploidy distribution of dietary-restricted mice. Environ. Health Perspect. 101, 229-233. doi: 10.1289/ehp.93101s5229
53. Mahan, C. E. (2014). A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents. J. Thromb. Thrombolysis. 37, 271-278. doi: 10.1007/s11239-013-0927-7
54. McGrath, J. C., Drummond, G. B., McLachlan, E. M., Kilkenny, C., and Wainwright, C. L. (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br. J. Pharmacol. 160, 1573-1576. doi: 10.1111/j.1476-5381.2010.00873.x
55. Mehvar, R. (2000). Dextrans for target and sustained delivery of therapeutic and imaging agents. J. Control. Release. 69, 1-25. doi: 10.1016/S0168-3659(00)00302-3
56. Mehvar, R., Robinson, M. A., and Reynolds, J. M. (1994). Molecular weight dependent tissue accumulation of Dextrans: in vivo studiem in rats. J. Pharm. Sci. 83, 1495-1499. doi: 10.1002/jps.2600831024
57. Messina, A., Davies, D. J., and Ryan, G. B. (1989). Protamine sulphate-induced proteinuria: the roles of glomerular injury and depletion of polyanion. J. Pathol. 158, 147-156. doi: 10.1002/path.1711580210
58. Morel, D. R., Lowenstein, D., Nguyenduy, T., Robinson, D. R., Repine, J. E., Chenoweth, D. E., et al. (1988). Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep: evidence for the role of reactive oxygen metabolites following nonimmunological complement activation. Circ. Res. 62, 905-915.
59. Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., et al. (2015). Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131, e29-e322. doi: 10.1161/CIR.0000000000000152
60. Nakane, S., Matsumoto, S., Takakura, Y., Hashida, M., and Sezaki, H. (1988). The accumulation mechanism of cationic mitomycin C-dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes. J. Pharm. Pharmacol. 40, 1-6. doi: 10.1111/j.2042-7158.1988.tb05139.x
61. Nashida, K., Mihara, K., Takino, T., Nakane, S., Takakura, Y., Hashida, M., et al. (1991). Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 8, 437-444. doi: 10.1023/A:1015886708598
62. Nayak, N. C., Sathar, S. A., Mughal, S., Duttagupta, S., Mathur, M., and Chopra, P. (1996). The nature and significance of liver cell vacuolation following hepatocellular injury-an analysis based on observations on rats rendered tolerant to hepatotoxic damage. Virchows. Arch. 428, 353-365. doi: 10.1007/BF00202202
63. Nishida, K., Tonegawa, C., Nakane, S., Takakura, Y., Hashida, M., and Sezaki, H. (1990). Effect of electric charge on the hepatic uptake of macromolecules in the rat liver. Int. J. Pharm. 65, 7-17. doi: 10.1016/0378-5173(90)90003-M
64. Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., et al. (2015). Idarucizumab for dabigatran reversal. N. Engl. J. Med. 373, 511-520. doi: 10.1056/NEJMoa1502000
65. Ransdell, H. T., Haller, J. A. Jr., Stowens, D., and Barton, P. B. (1965). Renal toxicity of polybrene (hexadimethrine bromide). J. Surg. Res. 5, 195-199. doi: 10.1016/S0022-4804(65)80086-5
66. Regan-Shaw, S., Nihil, M., and Ahmad, N. (2008). Dose translation from animals to human studies revised. FASEB. J. 22, 659-661. doi: 10.1096/fj.07-9574LSF
67. Saito, T., Sumithran, E., Glasgow, E. F., and Atkins, R. C. (1987). The enhancement of aminonucleoside nephrosis by co-administration of protamine. Kidney Int. 32, 691-699. doi: 10.1038/ki.1987.262
68. Shenoi, R. A., Kalathottukaren, M. T., Travers, R. J., Lai, B. F. L., Creag, A. L., Lange, D., et al. (2014). Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci. Transl. Med. 6, 260ra150. doi: 10.1126/scitranslmed.3009427
69. Shenoy, S., Harris, R. B., and Sobel, M. (1999). Development of heparin antagonists with focused biological activity. Curr. Pharm. Des. 5, 965-986.
70. Smith, S., Scarth, E., and Sasada, M. (2011). Drugs in Anaesthesia and Intensive Care, 4th Edn. New York, NY: Oxford University Press Inc.
71. Stafford-Smith, M., Lefrak, E. A., Qazi, A. G., Welsby, I. J., Barber, L., Hoeft, A., et al. (2005). Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 103, 229-240. doi: 10.1097/01.sa.0000203207.11554.86
72. Stock, R. J., Cilentom, E. V., and McCuskey, R. S. (1989). A quantitative study of fluorescein isothiocyaniane-dextran transport in microcirculation of the isolated perfused rat liver. Hepatology 9, 75-82. doi: 10.1002/hep.1840090112
73. Styles, J. A. (1993). Measurement of ploidy and cell proliferation in the rodent liver. Environ. Health. Perspect. 101, 67-71.
74. Tankiewicz, A., Pawlak, D., Pawlak, K., Szwec, D., Misliwiec, M., and Buczko, W. (2005). Anthranilic acid-uraemic toxin damaged red cell's membrane. Int. Urol. Nephrol. 37, 621-627. doi 10.1007/s11255-005-0395-x
75. Tobias, J. D. (2005). "Intraoperative strategies for transfusion-free surgery, " in Transfusion-Free Medicine and Surgery, ed N. Jabbour (Malden, MA: Blackwell Publishing), 75-113.
76. Transparency Market Research (2015). Heparin Market-Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014-2022. Available at: http://globenewswire.com/news-release/2015/10/20/778033/10153283/en/LMWH-is-the-Dominant-Heparin-Product-Market-in-Europe-and-is-Expected-to-Reach-USD-3-14-Billion-in-2022-Transparency-Market-Research.html (last accessed November 2015)
77. Vehanskarl, V. M., Rooter, E. R., Geemuth, F. G., and Robson, A. M. (1982). Glomerular charge and urinary protein excretion: effects of systemic and intrarenal polycation infusion in the rat. Kidney Int. 20, 127-135. doi: 10.1038/ki.1982.144
78. Vos, S. C., Hage, J. J., Woerdeman, L. A., and Noordanus, R. (2002). Acute renal failure during dextran-40 antithrombotic prophylaxis: report of two microsurgical cases. Ann. Plast. Surg. 48, 193-196. doi: 10.1097/00000637-200202000-00014
79. Wardrop, D., and Keeling, D. (2008). The story of the discovery of heparin and warfarin. Brit. J. Pharmacol. 141, 757-763. doi: 10.1111/j.1365-2141.2008.07119.x
80. Wu, H. F., Lundblad, R. L., and Church, F. C. (1995). Neutralization of heparin activity by neutrophil lactoferrin. Blood 85, 421-428.